India Pharma Outlook says the country's drug industry is shifting past scale toward peptides, antibody drug conjugates, complex generics and diagnostics.
Recap by typeshit. Post by @indiapharmaoutlook on Instagram.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
After GLP-1 drugs missed out on the physiology and medicine prize, The Chemical Breakdown podcast team runs through their chemistry Nobel predictions.
New WHO childhood obesity guidance cites unknown effects on growth and mental health, while Novo, Lilly, AstraZeneca and Pfizer keep testing the drugs in kids.
Loading…